Metabolic Phenotyping During Organ Support: Clinical Relevance and Emerging Approaches

Abstract

Metabolic phenotyping during organ support represents a paradigm shift in the management of critically ill patients. By leveraging advanced technologies and integrative approaches, clinicians can gain deeper insights into dynamic metabolic alterations, enabling individualized therapy. This review synthesizes current knowledge on metabolic phenotyping in the context of organ support, exploring epidemiology, pathophysiology, risk factors, clinical manifestations, diagnostic modalities, management strategies, recent advances, and guideline-based recommendations to inform best practices in critical care.

Introduction

Critical illness frequently necessitates organ support, such as mechanical ventilation, renal replacement therapy (RRT), or extracorporeal membrane oxygenation (ECMO). The metabolic perturbations accompanying organ failure and its support modalities are complex and heterogeneous. Traditional approaches using standard biochemical markers may fail to capture the full spectrum of metabolic derangements. Metabolic phenotyping—the comprehensive analysis of metabolites, metabolic pathways, and their clinical implications—offers the potential to tailor support strategies and improve outcomes. This article reviews the scientific basis, clinical applications, and future prospects of metabolic phenotyping in patients undergoing organ support.

Epidemiology / Disease Burden

The global burden of critical illness requiring organ support is substantial, with millions of patients admitted to intensive care units (ICUs) annually. Sepsis, acute respiratory distress syndrome (ARDS), acute kidney injury (AKI), and cardiac dysfunction are leading causes of multi-organ failure. Mortality rates for patients requiring multi-organ support remain high, ranging from 30% to 60% depending on the underlying etiology and comorbidities. Despite advances in supportive technologies, inter-individual variability in metabolic responses contributes to unpredictable outcomes, highlighting the need for precision approaches such as metabolic phenotyping.

Pathophysiology

Organ dysfunction triggers profound metabolic changes, including alterations in glucose, lipid, and protein metabolism, mitochondrial dysfunction, and dysregulated energy production. Organ support modalities further modulate these pathways. Mechanical ventilation may induce hypercapnia and acid-base shifts, RRT alters fluid and solute balances, and ECMO impacts oxygen delivery and metabolic waste clearance. These interventions can mask, exacerbate, or modify the underlying metabolic phenotype, necessitating sophisticated tools to monitor and interpret metabolic fluxes. Omics technologies—such as metabolomics and proteomics—enable high-resolution mapping of metabolic signatures, facilitating a systems biology understanding of critical illness.

Risk Factors

Patient-specific factors—including age, pre-existing metabolic conditions, nutritional status, and genetic predispositions—significantly influence metabolic responses during organ support. The severity and duration of organ dysfunction, the type of support modality used, and concurrent therapies (e.g., vasopressors, corticosteroids, nutritional interventions) also shape metabolic phenotypes. Notably, patients with diabetes, obesity, or chronic kidney disease may exhibit distinct metabolic trajectories, which can inform risk stratification and individualized management.

Clinical Features

Metabolic derangements manifest clinically as dysglycemia, lactic acidosis, catabolic states, electrolyte imbalances, and altered mental status. These features are often non-specific and may be confounded by the effects of organ support. For example, continuous RRT can obscure the diagnosis of hyperkalemia or acidosis, while ECMO may lead to variable glucose requirements and altered pharmacokinetics. Recognizing and interpreting these clinical features in the context of ongoing support is critical for timely intervention and prevention of secondary complications.

Diagnosis

Traditional diagnostic approaches rely on serial measurements of blood gases, lactate, glucose, urea, creatinine, and other metabolic markers. However, these parameters provide limited insight into the complexity of metabolic alterations during organ support. Metabolic phenotyping utilizes advanced technologies such as mass spectrometry, nuclear magnetic resonance (NMR) spectroscopy, and multiplex assays to quantify a broad spectrum of metabolites. Integrating these data with clinical variables and organ support parameters enables precise characterization of metabolic states. Emerging approaches also incorporate machine learning algorithms to identify patterns predictive of clinical deterioration or recovery.

Treatment & Management

Effective management of metabolic disturbances during organ support requires a multifaceted approach. Nutritional support is tailored to metabolic demands, with close monitoring of caloric intake, protein requirements, and micronutrient status. Glycemic control is individualized based on dynamic assessments of insulin sensitivity and endogenous glucose production. Electrolyte and acid-base management are adjusted in real-time, accounting for the effects of RRT or ECMO. Pharmacological interventions may include insulin, bicarbonate, carnitine, or metabolic modulators. Importantly, metabolic phenotyping guides these interventions, enabling real-time optimization of therapy and avoidance of iatrogenic harm.

Recent Advances / Emerging Therapies

Recent advances in metabolomics and systems biology have revolutionized our understanding of metabolic adaptation during organ support. High-throughput platforms now allow bedside profiling of metabolic intermediates, offering actionable insights. Studies have demonstrated that specific metabolic signatures—such as elevations in branched-chain amino acids or acylcarnitines—correlate with patient trajectories and response to therapy. Personalized nutrition and metabolic modulation, guided by phenotypic data, are under investigation in clinical trials. Furthermore, artificial intelligence-driven decision support systems are being developed to integrate metabolic phenotyping with clinical workflows, potentially transforming critical care management.

Guideline Recommendations

International guidelines increasingly recognize the importance of individualized metabolic monitoring during organ support. The Surviving Sepsis Campaign, KDIGO, and ESPEN guidelines recommend regular assessment of glucose, lactate, and nutritional status in critically ill patients. Although metabolic phenotyping is not yet universally adopted, expert consensus supports its use for complex cases or research protocols. Ongoing updates to guidelines are anticipated as evidence accumulates regarding the prognostic and therapeutic value of metabolic phenotyping.

Conclusion

Metabolic phenotyping during organ support offers unprecedented opportunities to personalize critical care, optimize outcomes, and advance our understanding of disease biology. By integrating cutting-edge technologies with established clinical practices, healthcare professionals can better navigate the complexities of metabolic derangements in critically ill patients. Continued research, technological innovation, and multidisciplinary collaboration are essential to fully realize the potential of metabolic phenotyping as a cornerstone of precision medicine in organ support.